Xiaobo, C., Majidi, M., Feng, M., Shao, R., Wang, J., Zhao, Y., . . . Roth, J. A. (2016). TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin. Sci Rep.
Stile di citazione ChicagoXiaobo, Cao, et al. "TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted By the Repurposed Drug Auranofin." Sci Rep 2016.
Citazione MLAXiaobo, Cao, et al. "TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted By the Repurposed Drug Auranofin." Sci Rep 2016.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.